Case Number: RT (M) Potential Audiences: Intent Doctor, Oncology Special Nurse, Resident Doctor

Similar documents
Breast Cancer with Brain Metastases: the Role and Treatment Consideration of Radiotherapy

Malignant Peripheral Nerve Sheath Tumor post Wide Excision with Multiple Lung Metastases: the Role and Treatment Consideration of RT

Case Number: RT (M) Potential Audiences: Intent Doctor, Oncology Special Nurse, Resident Doctor

How to Manage Esophagus Cancer Patients with ct3n0m0, stage III Disease?

Metastatic Bone Adenocarcinoma with Positive TTF-1 Tumor Stain with a Lung Mass: the Role and Treatment Consideration of RT

Huge Right SCF Mass in a Case of Double Cancer (Buccal Cancer and Hepatoma): the Role and Treatment Consideration of RT

Case Number: RT (M) Potential Audiences: Intent Doctor, Oncology Special Nurse, Resident Doctor

Lung Cancer with Mediastinum Invasion: the Consideration of Radiotherapy

How to Manage a Case of Stage-I Oropharyngeal Cancer with Very Close Cutting End Post-Operatively?

SAMPLE. Survivorship Care Plan for Lymphoma (Diffuse Large B-Cell) General Information. Care team

2007 ANNUAL SITE STUDY HODGKIN S LYMPHOMA

Dr. Noelle O Rourke Beatson Oncology Centre, Glasgow RADIOTHERAPY FOR LYMPHOMA???

Malignant related superior vena cava (SVC) syndrome

NICE Quality Standards and COF

APPROACH TO PLEURAL EFFUSIONS. Raed Alalawi, MD, FCCP

Case Scenario 1. Pathology report Specimen from mediastinoscopy Final Diagnosis : Metastatic small cell carcinoma with residual lymphatic tissue

Targeted Therapies in the Management of Non-Small Cell Lung Cancer. A Multi-Disciplinary Approach

Role of radiotherapy in the treatment of lymphoma in Lena Specht MD DMSc Professor of Oncology Rigshospitalet, University of Copenhagen Denmark

Management of Pleural Effusion

Lancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma:

Clinical Radiological Pathological Conference

Case 1: Question. 1.1 What is the main pattern of this HRCT? 1. Intralobular line 2. Groundglass opacity 3. Perilymphatic nodule

Guideline for the Follow-up of Patients with Gynaecological Malignancies

Radiation Therapy in SCLC. What is New? Prof. Dr. Hoda Abdel Baky El Bakry Cairo Cancer Institute Radiation Oncology Department

THORACIC MALIGNANCIES

National Optimal Lung Cancer Pathway

Newton Wellesley Hospital 2013

Case Scenario 1. The patient agreed to a CT guided biopsy of the left upper lobe mass. This was performed and confirmed non-small cell carcinoma.

Boot Camp Case Scenarios

Radiotherapy in aggressive lymphomas. Umberto Ricardi

Lung. 10/24/13 Chest X-ray: 2.9 cm mass like density in the inferior lingular segment worrisome for neoplasm. Malignancy cannot be excluded.

Breast Cancer Survivor Treatment Summary and Plan

Radiation and Hodgkin s Disease: A Changing Field. Sravana Chennupati Radiation Oncology PGY-2

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES

Supplementary Appendix

Lugano classification: Role of PET-CT in lymphoma follow-up

Radiotherapy for lymphoma

NCCN GUIDELINES ON PROTON THERAPY (AS OF 4/23/18) BONE (Version , 03/28/18)

All I Need Is The Air That I Breathe: A Case Study of Immunotherapy and Severe Pneumonitis

Case Scenario year-old white male presented to personal physician with dyspepsia with reflux.

Lymphocyte Predominant Hodgkin s Lymphoma. Case Presentation. How would you treat the patient?

Recording Toxicity: the QUANTEC model. Michela Buglione di Monale Nadia Pasinetti Cattedra di Radioterapia

NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)

Attachment #2 Overview of Follow-up

Oncologic Emergencies: When to call the Radiation Oncologist

Case Scenario #1 Larynx

RF Ablation: indication, technique and imaging follow-up

Radiotherapy in feline and canine head and neck cancer

Presentation material is for education purposes only. All rights reserved URMC Radiology Page 1 of 98

Effective local and systemic therapy is necessary for the cure of Ewing tumor Most chemotherapy regimens are a combination of cyclophosphamide,

Larry Tan, MD Thoracic Surgery, HSC. Community Cancer Care Educational Conference October 27, 2017

Treatment Planning for Breast Cancer: Contouring Targets. Julia White MD Professor

Comparison of Three Radiation Dose Levels after EBVP Regimen in Favorable Supradiaphragmatic Clinical Stages I-II Hodgkin s Lymphoma (HL):

SMALL CELL LUNG CANCER Updated Feb 2017 by Dr. Doreen Ezeife (PGY-5 Medical Oncology Resident, University of Calgary)

Update on Small Cell Lung Cancer

Shore Medical Center Site-Specific Study: Colorectal Cancer 2013

Non-Hodgkin Lymphoma in Clinically Difficult Situations

7.342 Chronic infection and inflammation: What are the consequences on your health? Instructors Eva Frickel and Sara Gredmark

Lymphoma is a cancer that develops in the white blood cells (lymphocytes) of the lymphatic system, which is part of the body's immune system.

Interventional Pulmonary Case Based Discussions (ATS) Ali Imran Saeed, MD University of New Mexico

Trimodality Therapy for Muscle Invasive Bladder Cancer

Lung Cancer Radiotherapy

LEUKAEMIA and LYMPHOMA. Dr Mubarak Abdelrahman Assistant Professor Jazan University

R-GDP: Rituximab, Gemcitabine, Dexamethasone &Cisplatin

Klinikleitung: Dr. Kessler Dr. Kosfeld Dr. Tassani-Prell Dr. Bessmann. Radiotherapy in feline and canine head and neck cancer.

BRONCHOGENIC CARCINOMA CHALLENGES IN EVALUATION

Understanding your diagnosis. Dr Graham Collins Consultant Haemtologist Oxford University Hospitals

Total Body Irradiation (TBI) Information for patients. Northern Centre for Cancer Care (NCCC) Freeman Hospital

Amanda Phillips, RVT

GUIDELINES FOR RADIOTHERAPY IN SPINAL CORD COMPRESSION THE CHRISTIE, GREATER MANCHESTER & CHESHIRE. Version:

North of Scotland Cancer Network Clinical Management Guideline for Oropharyngeal Cancer

A Practical Guide to PET adapted Therapy for Hodgkin Lymphoma

Tumor Board Discussions: Case 1

Impact of pre-treatment symptoms on survival after palliative radiotherapy An improved model to predict prognosis?

Update on Limited Small Cell Lung Cancer. Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver

ES-SCLC Joint Case Conference. Anthony Paravati Adam Yock

R-GDP: Rituximab, Gemcitabine, Dexamethasone &Cisplatin

Cancer of Unknown Primary (CUP) Protocol

Public Comment Period for Proposed Radiation Oncology Survivorship Care Plan Template

LUNG CANCER: LDCT DISCLOSURES NONE. Erika Swanson, MD Radiation Oncologist Ascension Columbia-St. Mary s February 1, /9/2018

A 64yo female with tuberculous empyema not improving on treatment: A tribute and farewell to Dr. Alphonse Kayembe

Non-Hodgkin lymphoma

Evidence tables from the systematic literature search for premature ovarian insufficiency surveillance in female CAYA cancer survivors.

Combined chemotherapy and Radiotherapy for Patients with Breast Cancer and Extensive Nodal Involvement.

COMPREHENSIVE CANCER CENTER/DESERT REGIONAL MEDICAL CENTER 2017 COMMUNITY OUTREACH SUMMARY AND OUTCOMES REPORT

Management of Cervical Cancer in Resource Limited Settings

Maria João Cardoso, MD, PhD

RADIOTHERAPY IN BREAST CANCER :

Hodgkin's Lymphoma. Symptoms. Types

Slide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology

Alexander Fosså, M.D. PhD.

Pediatric Lymphoma Update from the Children s Oncology Group

(1/5) PP7 - Spinal Epidural Anaplastic Large Cell Lymphoma associated with breast implants

ANAL CANCER Updated May 2016 by Dr. Daniel Yokom (PGY-5 Medical Oncology Resident, University of Toronto)

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

One stop shop. Natalie D. Klass, MD

Oral Cavity. 1. Introduction. 1.1 General Information and Aetiology. 1.2 Diagnosis and Treatment

Bringing the Fight to Cancer Annual Report

Pancreas Case Scenario #1

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES

Transcription:

Precursor T-Cell Lymphoblastic Lymphoma of the Mediastinum Post Chemotherapy with Disease Progression Post Radiotherapy and Salvage Chemotherapy with Residual Mediastinum Masses Post Re-Irradiation with Pericardial Effusion and Pleural Effusion: the Treatment Consideration of Further Care Case Number: RT2009 86-3(M) Potential Audiences: Intent Doctor, Oncology Special Nurse, Resident Doctor Purpose: to present a case of precursor T-cell lymphoblastic lymphoma of the mediastinum post chemotherapy with near complete response then rapid tumor re-growth post radiotherapy and salvage chemotherapy with residual mediastinum disease post re-irradiation with significant pericardial effusion and pleural effusion; to discuss the treatment consideration of further care Scenario: You are radiotherapy (RT) Intent Doctor/Special Nurse/Resident Doctor, and you are assigned to evaluate the following patient before visiting of your RT attending physician. Please review the following description carefully; your RT attending physician will visit this patient later and discuss with you after your review. Case Presentation: This 14 year-old male patient, 徐 OO, was referred to us for radiotherapy assessment of refractory mediastinum T-cell lymphoma. S: 1. In 2008/08, a huge mediastinum mass was found. 2. In 2008/09, tumor biopsy was done and pathology reported precursor T-lymphoblastic lymphoma. Definitive chemotherapy was done and good response was found. 3. In 2008/12, however, severe dry cough was found and chest CT showed tumor re-growth to near the original huge size. 4. In 2009/01, RT (2009/01, 1950 cgy in 13 fractions) was given, and partial response after RT was noted. Then, salvage chemotherapy was given. 5. In 2009/03, gross residual tumor mass (3-4 cm) was noted by a follow-up CT. 6. During 2009/03-2009/04, incomplete re-irradiation with 2700 cgy in 15 fractions was given to the residual mediastinum mass. 7. In 2009/04, he suffered from dyspnea and was sent to our ER for help. A following CT reported still residual mediastinum mass with significant peri-cardial effusion and pleural effusion. Histories: NDKA O: 1. General Condition: ECOG: 1-2, sitting on a wheelchair, mild dyspnea pattern 2. PE: (1). HEENT & SCF: no neck LNs, significant face and neck edema due to steroid effect was noted; (2). CHE: mild decrease breathing sound, right; (3). Others: neg. 3. ***Pathology in 2008/09, mediastinum tumor biopsy: precursor T-lymphoblastic lymphoma 4. Images: (1). Chest CT in 2009/04: still residual mediastinum mass with significant peri-cardial effusion and pleural effusion; pending formal report.

Key Image(s): Fig. 1. 2009/04, Chest CT Fig. 2. 2009/04, Chest CT Fig. 3. 2009/04, Chest CT

Questions & Discussions: (Please answer the following questions commented from your RT attending physician.) Q1: What are your findings/interpretations for the above key image(s)? Q2: What is your clinical cancer stage, according to the AJCC 2006, for this case? Q3: What is your pathologic cancer stage, according to the AJCC 2006, for this case? Q4: What are your Oncology Diagnosis / Assessments for this case? Q5: What is your Oncology Plan for this case? Q6: What is your Radiotherapy Plan for this case? (Please reply with the following form: Indication/Contraindication, Goal, Target & Volume, Technique, and Dose & Fractionation.)

Questions & Discussions: (with potential answers) (Please answer the following questions commented from your RT attending physician.) Q1: What are your findings/interpretations for the above key image(s)? A1: As described in the last attached page. Q2: What is your clinical cancer stage, according to the AJCC 2006, for this case? A2: Ann Arbor stage IB (2008/08, 13-cm bulky tumor); Ann Arbor r-stage IB (2008/12, 10-cm re-growth tumor); Ann Arbor rr-stage IB (2009/03, 4-5 cm) Q3: What is your pathologic cancer stage, according to the AJCC 2006, for this case? A3: no pathology stage can be defined in this case. Q4: What are your Oncology Diagnosis / Assessments for this case? A4: Precursor T-lymphoblastic lymphoma of the mediastinum, predominate on the anterior-upper mediastinum, Ann Arbor stage IB (2008/08, 13-cm bulky tumor), post definitive chemotherapy with near complete response (2008/10), with rapid disease progression (2008/12), Ann Arbor r-stage IB (2008/12, 10-cm re-growth tumor), post RT (2009/01, 1950 cgy in 13 fractions to the mediastinum mass), with partial response, post incomplete salvage chemotherapy, with gross residual tumor mass (2009/03), Ann Arbor rr-stage IB (2009/03, 4-5 cm), post re-irradiation (2009/04, 2700 cgy in 15 fractions, mediastinum mass), with disease progression (2009/04, peri-cardial effusion and pleural effusion) Q5: What is your Oncology Plan for this case? A5: Suggest peri-cardial and pleural effusion tapping for symptoms alleviation and cytology studies; suggest further salvage chemotherapy or bone marrow transplantation if indicated; no definitive indication for radiotherapy now; it may be a relative contra-indication for RT to the mediastinum region in this case due to prior high dose of RT in this region. Q6: What is your Radiotherapy Plan for this case? (Please reply with the following form: Indication/Contraindication, Goal, Target & Volume, Technique, and Dose & Fractionation.) A6: RT Plan may be designed as the following one: (1). Indication: no definitive indication for radiotherapy now; it may be a relative contra-indication for RT to the mediastinum region in this case due to prior high dose of RT in this region. (2). Goal: NA (3). Target & Volume: NA (4). Technique: NA (5). Dose & Fractionation: NA Further Readings & References: NCCN 2009 & Perez 2008 & AJCC 2006 Radiation Oncologist Hon-Yi Lin 2009/04/22

Key Image(s): (with marked) Fig. 1. 2009/04, Chest CT Fig. 1. Residual lymphoma mass over the pre-vascular space with size more than 5 cm (as the short white arrows); right pleural effusion (as the long white arrow) and minimal left pleural effusion were noted (as the white arrow head). Fig. 2. 2009/04, Chest CT Fig. 2. Significant right pleural effusion was noted (as the long white arrow); peri-cardial effusion was also found (as the short white arrow); minimal left pleural effusion was seen (as the white arrow head). Fig. 3. 2009/04, Chest CT Fig. 3. The caudal portion of the heart/peri-cardium showed significant peri-cardial effusion (as the short white arrows); significant pleural effusion was also noted (as the long white arrow); minimal left pleural effusion was seen (as the white arrow head).